CTLA4 and neoplasm: This mechanism can be hijacked by tumor cells to avoid elimination by immune cells, thus ICB therapy (e.g., anti-CTLA-4, anti-PD-1/PD-L1) was developed to counteract the immune suppressive microenvironment, thereby to strengthen the tumor-killing effects9.